how glp 1 medications are changing consumer behavior GLP-1 Sparks the Big Bang of Change GLP-1 CPG Consumer Trends |

July 2, 2023

International Journal of Food Science, 2019 , 4138534

Both have gone through clinical trials and the dosage schedule is set up in a way that is effective and safe for what they are used to treat

Semaglutid und Liraglutid zhlen zu den Glucagon-like-Peptid-1-Rezeptoragonisten (GLP-1-RA)

For example, in the LEADER trial, when compared with placebo, liraglutide decreased the incidence of major cardiovascular events (MACE) by 13%, cardiovascular death by 22% and all-cause death by 15% among T2DM patients with CVD, on a standard treatment basis [4]

Elizabeth Kapral, director of oral medicine at the University at Buffalo